1,710
Participants
Start Date
March 28, 2022
Primary Completion Date
July 31, 2026
Study Completion Date
March 31, 2027
LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet
LF111 (drospirenone 4 mg tablet orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28) or drospirenone (DRSP) 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (USA only). Subjects in the USA who choose to use the hormonal contraceptive method may choose between LF111 and DRSP 3.5 mg chewable tablets. The DRSP 3.5 mg chewable tablets are not available to subjects in Europe. Subjects in Europe who choose to use the hormonal contraceptive method will only receive LF111.
RECRUITING
M3 Wake Research, Raleigh
RECRUITING
M3 Wake Research, Inc., Sandy Springs
RECRUITING
Cornerstone Research Institute, Longwood
RECRUITING
Health Care Family Rehab & Research Center, Hialeah
RECRUITING
Vital Pharma Research, Hialeah
RECRUITING
Advanced Clinical Research Network, Coral Gables
RECRUITING
Florida Pharmaceutical Research and Associates, Inc., South Miami
RECRUITING
New Age Medical Research Corporation, Miami
RECRUITING
Comprehensive Clinical Research, LLC, West Palm Beach
RECRUITING
Lillestol Research LLC, Fargo
RECRUITING
Meridian Clinical Research, Norfolk
RECRUITING
Clinical Trials Management, LLC - Southshore, Metairie
RECRUITING
Tandem Clinical Research, Marrero
RECRUITING
Signature Gyn Services, Fort Worth
RECRUITING
TMC Life Research, Inc., Houston
RECRUITING
Corpus Christi Women's Clinic, Corpus Christi
RECRUITING
Velocity Clinical Research, Denver
RECRUITING
Family Care Research, Boise
RECRUITING
Cactus Clinical Research, Inc., Phoenix
RECRUITING
Seattle Clinical Research Center, Seattle
Lead Sponsor
Collaborators (1)
Chemo Research
INDUSTRY
Insud Pharma
INDUSTRY